NCT01838590View on ClinicalTrials.gov

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

August 31, 2014

Conditions
Hepatitis C Virus
Interventions
DRUG

SOF

Sofosbuvir (SOF) 400 mg tablet administered orally once daily

DRUG

RBV

Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Trial Locations (2)

Unknown

Al Mansurah

Cairo

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY